William J. Metzler
University of Colorado Boulder
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by William J. Metzler.
Biochemistry | 1993
William J. Metzler; Keith L. Constantine; Mark S. Friedrichs; Aneka Bell; Eileen G. Ernst; Thomas B. Lavoie; Luciano Mueller
Abstract Human profilin is a 15-kDa protein that plays a major role in the signaling pathway leading to cytoskeletal rearrangement. Essentially complete assignment of the 1H, 13C, and 15N resonances of human profilin have been made by analysis of multidimensional, double- and triple-resonance nuclear magnetic resonance (NMR) experiments. The deviation of the 13C alpha and 13C beta chemical shifts from their respective random coil values were analyzed and correlate well with the secondary structure determined from the NMR data. Twenty structures of human profilin were refined in the program X-PLOR using a total of 1186 experimentally derived conformational restraints. The structures converged to a root mean squared distance deviation of 1.5 A for the backbone atoms. The resultant conformational ensemble indicates that human profilin is an alpha/beta protein comprised of a seven-stranded, antiparallel beta-sheet and three helices. The secondary structure elements for human profilin are quite similar to those found in Acanthamoeba profilin I [Archer, S. J., Vinson, V. K., Pollard, T. D., & Torchia, D. A. (1993), Biochemistry 32, 6680-6687], suggesting that the three-dimensional structure of Acanthamoeba profilin I should be analogous to that determined here for human profilin. The structure determination of human profilin has facilitated the sequence alignment of lower eukaryotic and human profilins and provides a framework upon which the various functionalities of profilin can be explored. At least one element of the actin-binding region of human profilin is an alpha-helix. Two mechanisms by which phosphatidylinositol 4,5-bisphosphate can interfere with actin-binding by human profilin are proposed.
Journal of Medicinal Chemistry | 2012
Samuel W. Gerritz; Weixu Zhai; Shuhao Shi; Shirong Zhu; Jeremy H. Toyn; Jere E. Meredith; Lawrence G. Iben; Catherine R. Burton; Charles F. Albright; Andrew C. Good; Andrew J. Tebben; Jodi K. Muckelbauer; Daniel M. Camac; William J. Metzler; Lynda S. Cook; Ramesh Padmanabha; Kimberley A. Lentz; Michael J. Sofia; Michael A. Poss; John E. Macor; Lorin A. Thompson
This report describes the discovery and optimization of a BACE-1 inhibitor series containing an unusual acyl guanidine chemotype that was originally synthesized as part of a 6041-membered solid-phase library. The synthesis of multiple follow-up solid- and solution-phase libraries facilitated the optimization of the original micromolar hit into a single-digit nanomolar BACE-1 inhibitor in both radioligand binding and cell-based functional assay formats. The X-ray structure of representative inhibitors bound to BACE-1 revealed a number of key ligand:protein interactions, including a hydrogen bond between the side chain amide of flap residue Gln73 and the acyl guanidine carbonyl group, and a cation-π interaction between Arg235 and the isothiazole 4-methoxyphenyl substituent. Following subcutaneous administration in rats, an acyl guanidine inhibitor with single-digit nanomolar activity in cells afforded good plasma exposures and a dose-dependent reduction in plasma Aβ levels, but poor brain exposure was observed (likely due to Pgp-mediated efflux), and significant reductions in brain Aβ levels were not obtained.
Journal of Medicinal Chemistry | 2015
Daniel L. Cheney; Jeffrey M. Bozarth; William J. Metzler; Paul E. Morin; Luciano Mueller; John A. Newitt; Alexandra H. Nirschl; Alan R. Rendina; James Tamura; Anzhi Wei; Xiao Wen; Nicholas R. Wurtz; Dietmar A. Seiffert; Ruth R. Wexler; E. Scott Priestley
A multidisciplinary, fragment-based screening approach involving protein ensemble docking and biochemical and NMR assays is described. This approach led to the discovery of several structurally diverse, neutral surrogates for cationic factor VIIa P1 groups, which are generally associated with poor pharmacokinetic (PK) properties. Among the novel factor VIIa inhibitory fragments identified were aryl halides, lactams, and heterocycles. Crystallographic structures for several bound fragments were obtained, leading to the successful design of a potent factor VIIa inhibitor with a neutral lactam P1 and improved permeability.
Journal of Medicinal Chemistry | 2008
Keith L. Constantine; Luciano Mueller; William J. Metzler; Patricia A. McDonnell; Gordon Todderud; Valentina Goldfarb; Yi Fan; John A. Newitt; Susan E. Kiefer; Mian Gao; David R. Tortolani; Wayne Vaccaro; John S. Tokarski
Fragment-like inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK2) include 5-hydroxyisoquinoline (IC50 approximately 85 microM). Modeling studies identified four possible binding modes for this compound. Two-dimensional (1)H-(1)H NOESY data obtained with selectively protonated samples of MK2 in complex with 5-hydroxyisoquinoline demonstrated that two of the four predicted binding modes are well populated. A second small isoquinoline was subsequently shown to bind in a single mode. NMR and modeling studies using this general approach are expected to facilitate scaffold hopping and structure-guided elaborations of fragment-like kinase inhibitor cores.
Archive | 1996
Thorunn Rafnar; William J. Metzler; David G. Marsh
Ragweed pollen contains multiple allergenic components that differ in their ability to elicit an allergic response in humans. There are the “major” allergens, such as Amb a I, to which the great majority of ragweed-allergic individuals develop antibodies. Conversely, there are proteins that are reactive in a small percentage (10–20%) of ragweed-allergic subjects, even though they can be highly immunogenic in susceptible individuals. These are referred to as “minor” allergens. A group of minor allergens, the Amb Vs, has been used as a model to study the genetics of human immune response. The Amb Vs were selected for two primary reasons. First, the immunizing doses are extremely low; for Amb a V the dosage is probably less than 60 ng per year in the Baltimore area (Marsh, 1975). Under these conditions approximately 10% of the ragweed-allergic population develop IgE antibody and a somewhat greater portion develop IgG antibody to Amb a V (Marsh et al., 1982a). This condition mimics the responder/nonresponder delineation observed in experimental animals. Second, the Amb Vs’ small size and simple structure suggested that immune recognition might be limited to a single, or very few, immunodominant epitopes. Thus, in the polymorphic human population, only individuals with a particular genetic makeup would be responsive to these allergens. Recently, studies of the Amb Vs have been expanded to include analysis of the molecular interactions that occur during immune response to inhaled allergens.
Biochemistry | 1993
William J. Metzler; Keith L. Constantine; Mark S. Friedrichs; Aneka Bell; Eileen G. Ernst; Thomas B. Lavoie; Luciano Mueller
Biochemistry | 1989
William J. Metzler; Dennis R. Hare; Arthur Pardi
Journal of the American Chemical Society | 1996
William J. Metzler; Michael Wittekind; Valentina Goldfarb; Luciano Mueller; Bennett T. Farmer
Journal of Molecular Biology | 1990
William J. Metzler; Chuan Wang; Douglas B. Kitchen; Ronald M. Levy; Arthur Pardi
Biochemistry | 2005
Michael G. Kornacker; Zhihong Lai; Mark R. Witmer; Jianghong Ma; Joseph P. Hendrick; Ving G. Lee; Douglas James Riexinger; Claudio Mapelli; William J. Metzler; Robert A. Copeland